- $15.57bn
- $14.73bn
- $2.32bn
Annual cashflow statement for Exelixis, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 30th | 2023 December 29th | 2025 January 3rd | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 53 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 231 | 182 | 208 | 521 | 783 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 149 | 233 | 247 | 223 | 138 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -39 | -12.8 | -14 | -13.5 | -191 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 401 | 363 | 333 | 700 | 884 |
| Capital Expenditures | -64.2 | -27.7 | -40.5 | -28.4 | -8.43 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 21.3 | -497 | 13.5 | -88.3 | 359 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -42.9 | -524 | -27 | -117 | 350 |
| Financing Cash Flow Items | -39.1 | — | -29.1 | -38.6 | -71.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -14.8 | 0.586 | -546 | -629 | -970 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 343 | -161 | -240 | -45.6 | 265 |